Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telaprevir rollover study for virologic failures from C216 control arm
NL-OMON32715Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of telaprevir, peginterferon alfa-2a and ribavirin in hepatitis C virus infection, sponsored by Janssen Pharmaceutical. Primary endpoint: Sustained virologic response at 24 weeks after end of treatment. Started Jun 2010; status: recruiting.
02
Drugs
telaprevirpeginterferon alfa-2aribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON32715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32715.